GeoVax Labs, Inc. (Nasdaq: GOVX) announced the expansion of its oncology development strategy to include assessments of additional solid tumor targets for Gedeptin, its gene-directed enzyme prodrug therapy. The initiative builds on recent momentum with checkpoint inhibitors and the landmark KEYNOTE-689 trial results in head and neck cancer.
Working closely with its oncology advisory team including the Winship Cancer Institute of Emory University, GeoVax is evaluating the combination of Gedeptin with immune checkpoint inhibitors in preclinical models of several solid tumor types. These models are designed to validate Gedeptin’s mechanism—localized intratumoral cytotoxicity that also primes systemic immune responses—in tumor settings beyond head and neck cancer such as triple negative breast cancer and cutaneous malignancies.
GeoVax previously announced updated plans for a Phase 2 clinical trial, AdPNP-203, which will evaluate the addition of intra-tumoral Gedeptin and intravenous fludarabine to recently approved neoadjuvant pembrolizumab as first-line treatment of patients with head and neck squamous cell carcinoma eligible for curative surgery. The trial is designed to assess major pathological response and associated immunologic and biomarker outcomes following two pre-surgical cycles of therapy, as well as event-free survival over a one-year period. Gedeptin’s tumor-targeting, immune-sensitizing mechanism may help overcome the limitations of checkpoint monotherapy by enhancing immune activation within the tumor microenvironment. Trial initiation is planned for the second half of 2026.
The strategic rationale includes checkpoint synergy, as Gedeptin directly debulks tumors and enhances immune visibility, positioning it as a potential force multiplier for checkpoint inhibitors. Therapeutic expansion into additional solid tumors could support Gedeptin’s clinical evaluation in new indications. The KEYNOTE-689 trial demonstrated the transformative potential of neoadjuvant checkpoint therapy in head and neck cancer, underscoring the urgency and timeliness of expanding combination approaches such as Gedeptin plus Keytruda into additional tumor types.
David A. Dodd, Chairman & CEO of GeoVax, commented: “We view the expansion of Gedeptin development beyond head and neck cancer as addressing a critically important area of solid tumor cancer therapy and a major value-creation opportunity. By leveraging the strengths of our oncology advisors and validated checkpoint inhibitor backbones, we aim to evaluate that Gedeptin’s tumor-debulking and immune-priming effects can potentially improve outcomes in a broader range of solid tumor cancers. The KEYNOTE-689 results provide important context, showing how immune-sensitizing strategies like Gedeptin are increasingly vital to maximizing checkpoint efficacy.”
Dr. Kelly T. McKee, Chief Medical Officer, added: “Our preclinical efforts will provide in-vivo proof of concept for expanding Gedeptin-checkpoint inhibitor combination therapy into additional solid tumor types. This is a natural evolution of our program and ensures we remain positioned at the forefront of immuno-oncology innovation.”
GeoVax anticipates early readouts from its preclinical modeling work, with the results supporting the design of potential clinical trials in selected solid tumor indications. In parallel, the Company is targeting the initiation of its Phase 2 clinical trial of Gedeptin in combination with Keytruda for head and neck cancer in the second half of 2026. Potential collaborative discussions continue, with the expectation of some form of partnership or collaboration to occur relative to both the clinical development and the potential commercialization of Gedeptin.
